(Q45172279)

English

Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride

scientific article published in February 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

0 references

Boris B Quednow

2

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Thomas E. Schlaepfer

4

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

5

object named as

Wolfgang Maier

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

1

object named as

Michael Wagner

0 references

author name string

Jens Westheide

3

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Kai-Uwe Kühn

6

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

language of work or name

0 references

publication date

1 February 2005

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Neuropsychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

381-390

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.npp.1300626

0 references

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Another view of therapy for cognition in schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

The Continuous Performance Test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

A meta-analysis of the efficacy of second-generation antipsychotics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

What are the functional consequences of neurocognitive deficits in schizophrenia?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Longitudinal study of symptoms and cognitive function in chronic schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Cognitive effects and antipsychotic treatment.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Risperidone versus haloperidol on secondary memory: can newer medications aid learning?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Atypical antipsychotic medications and the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Opposing roles for dopamine and serotonin in the modulation of human spatial working memory functions.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Risperidone in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

The role of serotonin in antipsychotic drug action

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Clozapine: new research on efficacy and mechanism of action

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Atypical antipsychotic drugs improve cognition in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Deficits on subject-ordered tasks after frontal- and temporal-lobe lesions in man.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Action (verb naming) fluency as an executive function measure: convergent and divergent evidence of validity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Clinical trial response and dropout rates with olanzapine versus risperidone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Atypical antipsychotics and cognition in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

The cognitive efficacy of atypical antipsychotics in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Extrapyramidal symptoms in patients treated with risperidone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

21 January 2018

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

7 January 2021

based on heuristic

inferred from DOI database lookup

Cognitive impairment in schizophrenia: its impact on social functioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

7 January 2021

based on heuristic

inferred from DOI database lookup

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

7 January 2021

based on heuristic

inferred from DOI database lookup

The physiological role of 5-HT2A receptors in working memory

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300626

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.NPP.1300626

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45172279&oldid=2069036557"